mesalamine (Asacol HD) vs Mesalamine (Pentasa)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: Aminosalicylate · full Ulcerative Colitis pipeline

mesalamine (Asacol HD)

Rights held by AbbVie

US approval withdrawn in Ulcerative Colitissmall molecule
Partial signal

NCT00577473 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 301 participants, comparing mesalamine 4.8 g/day with mesalamine 2.4 g/day. The primary clinical and sigmoidoscopy-based treatment-success endpoint was not significantly different between doses (p=0.4411), so the results provide well-controlled but inconclusive evidence that the higher dose is more effective.

No aligned efficacy figure on record for this race.

Mesalamine (Pentasa)

Marketed by Takeda Pharmaceutical Company and partners

Approved in Ulcerative Colitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointmesalamine (Asacol HD)Mesalamine (Pentasa)
Clinical remission (induction)—Not posted · NCT00548574—Not posted · NCT00209300
Clinical remission (maintenance)—Not posted · NCT00548574—Not posted · NCT00209300
Clinical response (induction)—Not posted · NCT00548574—Not posted · NCT00209300
Endoscopic improvement (induction)—Not posted · NCT00548574—Not posted · NCT00209300
Corticosteroid-free remission (maintenance)—Not posted · NCT00548574—Not posted · NCT00209300

Clinical remission (induction)

mesalamine (Asacol HD)
—Not posted · NCT00548574
Mesalamine (Pentasa)
—Not posted · NCT00209300

Clinical remission (maintenance)

mesalamine (Asacol HD)
—Not posted · NCT00548574
Mesalamine (Pentasa)
—Not posted · NCT00209300

Clinical response (induction)

mesalamine (Asacol HD)
—Not posted · NCT00548574
Mesalamine (Pentasa)
—Not posted · NCT00209300

Endoscopic improvement (induction)

mesalamine (Asacol HD)
—Not posted · NCT00548574
Mesalamine (Pentasa)
—Not posted · NCT00209300

Corticosteroid-free remission (maintenance)

mesalamine (Asacol HD)
—Not posted · NCT00548574
Mesalamine (Pentasa)
—Not posted · NCT00209300
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

mesalamine (Asacol HD): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.

Mesalamine (Pentasa): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mesalamine (Asacol HD)'s landscape · Mesalamine (Pentasa)'s landscape